Published on 29/11/2025

Risk-Based Reduction of Bridge Testing

The pharmaceutical industry faces continuous scrutiny and challenges in ensuring the quality and efficacy of biosimilars. With stringent regulations from organizations like the FDA, EMA, and MHRA, biosimilar developers must employ rigorous methods to establish analytical comparability. This tutorial provides a comprehensive step-by-step guide on risk-based reduction of bridge testing, focusing on key areas such as Critical Quality Attribute (CQA) mapping, fingerprint analytics, process drift monitoring, equivalence testing, and bridging justifications. The culmination of these strategies can enhance the confidence in biosimilar quality, thus facilitating regulatory approval.

Step 1: Understanding Biosimilar Analytical Comparability

Biosimilar analytical comparability is critical for validating the similarity of a biosimilar to its reference product. Regulatory authorities require thorough assessments of comparability to ensure that the biosimilar functions effectively and delivers as intended. Analytic methods span from identity testing to functional assays, all aimed at detecting significant differences between the biosimilar and its reference counterpart.

The key components in biosimilar analytical comparability include:

• Characterization of the reference product.
• Selection of appropriate comparative analytical methodologies.
• Statistical analysis of the data to assess variances.

In this step, it is essential to align with published guidelines from the EMA and the FDA, focusing on Q5E comparability and Q6B specifications. Thorough documentation and rigorous execution of analytical methods aid in justifying the process for biosimilar approval.

Step 2: Performing CQA Mapping

Critical Quality Attributes (CQAs) are physical, chemical, biological, and microbiological properties or characteristics that must be controlled to ensure product quality. CQA mapping is pivotal in establishing the relationship between process parameters and CQAs, ultimately facilitating equivalence testing.

The process for effective CQA mapping includes the following steps:

1. Identify CQAs: Conduct an extensive risk assessment to identify all potential CQAs based on the product’s attributes,, mechanisms of action, and patient safety.
2. Document Interrelationships: Map CQAs against relevant Critical Process Parameters (CPP) and establish how variations in production conditions can affect them.
3. Implement Monitoring: Develop a Continuous Process Verification (CPV) strategy that includes in-line monitoring techniques and controls to ensure that production remains within acceptable limits.

This mapping activity not only addresses regulatory expectations but also aids in the ongoing lifecycle management of the product. In line with ICH Q8 guidelines, ensure all potential manufacturing variations are considered during the CQA mapping process.

Step 3: Utilizing Fingerprint Analytics

Fingerprint analytics is an innovative approach to perform in-depth analysis and comparison between the biosimilar and reference products. This method involves combining multiple analytical techniques to create a ‘fingerprint’ of the product’s entire profile, which can help in detecting subtle differences that might not be evident through traditional tests.

Implementing fingerprint analytics involves the following:

• Define Analytical Techniques: Use complementary methodologies such as mass spectrometry, High-Performance Liquid Chromatography (HPLC), and bioassays.
• Data Integration: Develop systems to integrate data across platforms to provide a holistic view of the biosimilar’s attributes. This assists in assessing minor variances effectively.
• Statistical Comparison: Employ robust statistical analysis methods to evaluate the similarity between the fingerprints of the biosimilar and the reference product.

Fingerprint analytics represent a significant advancement and can greatly enhance the analytical comparability assessments, allowing for a more nuanced understanding of product quality.

Step 4: Monitoring Process Drift

Process drift monitoring is crucial for ensuring sustained comparability over the biosimilar lifecycle. Variations in production processes or raw materials may lead to changes in the biosimilar’s profile, potentially affecting its safety and efficacy.

The approach to process drift monitoring involves:

1. Establish Baseline Profiles: Utilize historical data and fingerprint analytics to create baseline profiles important for robust manufacturing.
2. Continuous Monitoring: Integrate real-time monitoring systems to detect deviations from established baselines. Implement analytics solutions that aggregate data from production processes and perform trend analysis.
3. Investigate Outliers: Develop thorough procedures for investigating any significant deviations identified during the monitoring process. Utilize root cause analysis to understand and address these variances promptly.

Ensuring continual monitoring of process drift can enhance the control strategy’s effectiveness, meeting the ongoing requirements for equivalence testing set forth by regulatory authorities.

Step 5: Performing Equivalence Testing

Equivalence testing is an essential regulatory requirement for biosimilars. It establishes that the biosimilar is highly similar to the reference product in terms of CQAs and is not clinically significantly different in terms of safety and efficacy. Understanding the specifics of equivalence testing is critical to successful biosimilar development.

To perform effective equivalence testing, follow these steps:

1. Design Clinical Studies: Develop study designs that are sensitive enough to detect clinically relevant differences, often utilizing non-inferiority designs informed by regulatory guidelines.
2. Utilize Statistical Analysis: Employ statistical methods to analyze data from clinical trials. Ensure sample size calculations are adequately powered to draw conclusions about equivalence.
3. Document Results Rigorously: Thoroughly document findings and be prepared to present the data in compliance with FDA, EMA, and MHRA standards, particularly focusing on the language used in regulatory submissions.

Meeting equivalence testing requirements is paramount and sets the foundation for risk-based reduction in bridge testing. Regulatory bodies expect that this testing will substantiate the claims made in marketing authorization applications (MAA).

Step 6: Formalizing Bridging Justifications

Bridging justifications serve as essential documentation to validate differences in the manufacturing process or analytical methods of the biosimilar compared to the reference product. A thorough understanding of how to articulate these justifications is critical for regulatory approval.

Key points to focus on when formalizing bridging justifications include:

• Cite Regulatory Frameworks: Reference applicable guidelines, such as EMA’s biosimilar guidelines, which outline requirements for establishing comparability.
• Present Comprehensive Data: Provide an expansive dataset that supports the Justification process, including results from CQA mapping, fingerprint analytics, equivalence testing, and monitoring.
• Articulate Scientific Rationale: Clearly articulate the scientific rationale for changes in process and its impact on product quality, using strong evidence to back claims.

Bridging justifications play a pivotal role in establishing trust with regulatory bodies, ensuring that all changes are not only documented but scientifically validated and defensible.

Conclusion

The journey of proving biosimilar analytical comparability through risk-based reduction of bridge testing is intricate yet essential. By following the outlined steps—understanding biosimilar analytical comparability, performing CQA mapping, utilizing fingerprint analytics, monitoring process drift, conducting equivalence testing, and formalizing bridging justifications—pharmaceutical companies can systematically enhance their biosimilar development processes. This structured approach not only assures the safety and efficacy of biosimilars but also aligns with regulatory expectations from organizations like the FDA, EMA, and MHRA. The foundational work done in these areas can improve the likelihood of expedited approvals and successful market entries for biosimilars.